JPWO2019140271A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019140271A5 JPWO2019140271A5 JP2020538844A JP2020538844A JPWO2019140271A5 JP WO2019140271 A5 JPWO2019140271 A5 JP WO2019140271A5 JP 2020538844 A JP2020538844 A JP 2020538844A JP 2020538844 A JP2020538844 A JP 2020538844A JP WO2019140271 A5 JPWO2019140271 A5 JP WO2019140271A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- conjugate
- pharmaceutical according
- effective amount
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023186470A JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862617095P | 2018-01-12 | 2018-01-12 | |
| US62/617,095 | 2018-01-12 | ||
| US201862674483P | 2018-05-21 | 2018-05-21 | |
| US62/674,483 | 2018-05-21 | ||
| US201862700147P | 2018-07-18 | 2018-07-18 | |
| US62/700,147 | 2018-07-18 | ||
| US201862711423P | 2018-07-27 | 2018-07-27 | |
| US201862711421P | 2018-07-27 | 2018-07-27 | |
| US62/711,421 | 2018-07-27 | ||
| US62/711,423 | 2018-07-27 | ||
| US201862716788P | 2018-08-09 | 2018-08-09 | |
| US201862716796P | 2018-08-09 | 2018-08-09 | |
| US62/716,796 | 2018-08-09 | ||
| US62/716,788 | 2018-08-09 | ||
| PCT/US2019/013314 WO2019140271A2 (en) | 2018-01-12 | 2019-01-11 | Synergistic cancer treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023186470A Division JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021510702A JP2021510702A (ja) | 2021-04-30 |
| JPWO2019140271A5 true JPWO2019140271A5 (enExample) | 2022-01-19 |
Family
ID=67218383
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538844A Pending JP2021510702A (ja) | 2018-01-12 | 2019-01-11 | 相乗的がん治療 |
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538819A Pending JP2021510701A (ja) | 2018-01-12 | 2019-01-11 | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| JP2023186470A Active JP7703001B2 (ja) | 2018-01-12 | 2023-10-31 | 相乗的がん治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20200360545A1 (enExample) |
| EP (2) | EP3737383A4 (enExample) |
| JP (3) | JP2021510702A (enExample) |
| KR (2) | KR20200110377A (enExample) |
| CN (2) | CN111587115A (enExample) |
| AU (2) | AU2019206623A1 (enExample) |
| CA (2) | CA3087628A1 (enExample) |
| MX (3) | MX2020007442A (enExample) |
| RU (1) | RU2020126774A (enExample) |
| WO (2) | WO2019140271A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| MX2022002340A (es) * | 2019-08-28 | 2022-04-06 | Prolynx Llc | Inhibidores conjugados de la respuesta al daño de adn. |
| US20250325714A1 (en) * | 2022-04-14 | 2025-10-23 | National Institutes for Quantum Science and Technology | Single-polymer particles, active molecular complex, method for producing single-polymer particles, method for measuring tumor size, method for measuring fine structure within tumor, method for imaging biological tissue, drug delivery system, and contrast agent kit |
| WO2024030998A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Methods of treating cancer with long-acting topoisomerase i inhibitor |
| WO2024031005A2 (en) * | 2022-08-04 | 2024-02-08 | Prolynx Llc | Treating cancer with long-acting topoisomerase i inhibitor |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2256133B1 (en) | 1997-01-08 | 2016-12-14 | Sigma-Aldrich Co. LLC | Bioconjugation of macromolecules |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| AU2003253890A1 (en) | 2002-07-12 | 2004-02-02 | Biomarin Pharmaceutical Inc. | The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| US7495099B2 (en) | 2002-10-31 | 2009-02-24 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| CN1852740B (zh) | 2003-09-17 | 2011-05-11 | 耐科塔医药公司 | 多支链聚合物的药物前体 |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| CN101541332A (zh) | 2006-09-15 | 2009-09-23 | 安佐制药股份有限公司 | 含多官能连接基的靶向聚合物前药 |
| EP2307032A4 (en) * | 2008-05-22 | 2014-08-20 | Univ Ramot | NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| JP2012506380A (ja) | 2008-10-21 | 2012-03-15 | エンゾン ファーマシューティカルズ，インコーポレーテッド | ７−エチル−１０−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療 |
| EP2366105A1 (en) | 2008-11-18 | 2011-09-21 | Baxter International Inc. | Methods of determining polydispersity and/or molecular weight distribution of a polyethylene glycol sample |
| US8524214B2 (en) | 2009-05-28 | 2013-09-03 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| EP2501412B1 (en) | 2009-11-18 | 2017-03-29 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| WO2011140376A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from dendrimers |
| DK2566334T3 (en) | 2010-05-05 | 2018-07-23 | Prolynx Llc | MANAGED PHARMACEUTICAL RELEASE FROM SOLID CARRIERS |
| JP5977229B2 (ja) * | 2010-05-05 | 2016-08-24 | プロリンクス リミテッド ライアビリティ カンパニー | 巨大分子共役体からの徐放 |
| AR082806A1 (es) | 2010-08-30 | 2013-01-09 | Sun Pharma Advanced Res Co Ltd | Composicion farmaceutica estable |
| EP2640386B1 (en) | 2010-11-16 | 2017-01-18 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| JP5899241B2 (ja) | 2010-12-21 | 2016-04-06 | ネクター セラピューティクス | ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート |
| EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US9687562B2 (en) * | 2012-03-05 | 2017-06-27 | Ramot At Tel-Aviv University Ltd. | Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof |
| TWI486341B (zh) | 2012-05-18 | 2015-06-01 | Univ Kaohsiung Medical | 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法 |
| EP3004888A1 (en) | 2013-05-31 | 2016-04-13 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| WO2015051307A1 (en) | 2013-10-04 | 2015-04-09 | Prolynx Llc | Slow-release conjugates of sn-38 |
| WO2015066053A2 (en) * | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| WO2015118338A1 (en) | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| WO2015183876A1 (en) * | 2014-05-28 | 2015-12-03 | Memorial Sloan Kettering Cancer Center | Bimodal fluorophore-labeled liposomes and associated methods and systems |
| JP6342575B2 (ja) * | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
| US20160067362A1 (en) | 2014-08-16 | 2016-03-10 | Memorial Sloan Kettering Cancer Center | Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods |
| JP6378584B2 (ja) | 2014-08-29 | 2018-08-22 | キヤノン株式会社 | 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム |
| US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
| CA2981365A1 (en) | 2015-04-02 | 2016-10-06 | Merck Patent Gmbh | Imidazolonylquinolines and the use thereof as atm kinase inhibitors |
| BR112017020689A2 (en) * | 2015-04-07 | 2018-06-26 | Memorial Sloan-Kettering Cancer Center | nanoparticulate immunoconjugates |
| WO2016176462A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Central Florida Foundation, Inc. | Methods and compositions for theranostic nanoparticles |
| HK1257216A1 (zh) | 2015-08-20 | 2019-10-18 | 益普生生物制药有限公司 | 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法 |
| US10821195B2 (en) | 2015-09-10 | 2020-11-03 | Memorial Sloan Kettering Cancer Center | Compositions for therapeutics, targeted PET imaging and methods of their use |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| CN108697666A (zh) | 2016-02-29 | 2018-10-23 | 辛塔制药公司 | 用于治疗卵巢癌的组合疗法 |
| WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| AU2017257254B2 (en) | 2016-04-27 | 2022-02-24 | Immunomedics, Inc. | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| KR20190003630A (ko) | 2016-04-29 | 2019-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 악성 뇌 종양에서의 표적화된 입자 침투, 분포, 및 반응을 위한 조성물 및 방법 |
| CN106084005B (zh) | 2016-06-15 | 2020-02-14 | 广州军区广州总医院 | 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用 |
| CN107050471A (zh) | 2016-12-27 | 2017-08-18 | 中国药科大学 | 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用 |
-
2019
- 2019-01-11 CA CA3087628A patent/CA3087628A1/en active Pending
- 2019-01-11 AU AU2019206623A patent/AU2019206623A1/en not_active Abandoned
- 2019-01-11 MX MX2020007442A patent/MX2020007442A/es unknown
- 2019-01-11 JP JP2020538844A patent/JP2021510702A/ja active Pending
- 2019-01-11 CN CN201980008227.1A patent/CN111587115A/zh active Pending
- 2019-01-11 KR KR1020207023337A patent/KR20200110377A/ko not_active Ceased
- 2019-01-11 JP JP2020538819A patent/JP2021510701A/ja active Pending
- 2019-01-11 WO PCT/US2019/013314 patent/WO2019140271A2/en not_active Ceased
- 2019-01-11 CN CN201980008252.XA patent/CN111587126A/zh active Pending
- 2019-01-11 CA CA3087967A patent/CA3087967A1/en active Pending
- 2019-01-11 MX MX2020007306A patent/MX2020007306A/es unknown
- 2019-01-11 US US16/961,633 patent/US20200360545A1/en not_active Abandoned
- 2019-01-11 RU RU2020126774A patent/RU2020126774A/ru unknown
- 2019-01-11 US US16/961,640 patent/US11730836B2/en active Active
- 2019-01-11 KR KR1020207023338A patent/KR20200109345A/ko not_active Ceased
- 2019-01-11 EP EP19738883.8A patent/EP3737383A4/en active Pending
- 2019-01-11 AU AU2019208024A patent/AU2019208024A1/en not_active Abandoned
- 2019-01-11 WO PCT/US2019/013306 patent/WO2019140266A1/en not_active Ceased
- 2019-01-11 EP EP19738881.2A patent/EP3737416A4/en active Pending
-
2020
- 2020-07-13 MX MX2023005786A patent/MX2023005786A/es unknown
-
2023
- 2023-03-07 US US18/118,650 patent/US20230321286A1/en not_active Abandoned
- 2023-07-11 US US18/220,742 patent/US20240082436A1/en not_active Abandoned
- 2023-10-31 JP JP2023186470A patent/JP7703001B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Boulikas | Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin™. Lipoplatin™ as a chemotherapy and antiangiogenesis drug | |
| Begg et al. | Strategies to improve radiotherapy with targeted drugs | |
| Shabason et al. | Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic | |
| US20210077625A1 (en) | Ray tracing technique for wireless channel measurements | |
| JP7703001B2 (ja) | 相乗的がん治療 | |
| US20230190694A1 (en) | Compositions for and methods of precision cancer treatment | |
| CN113797341B (zh) | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 | |
| Wang et al. | Recent advances in use of topoisomerase inhibitors in combination cancer therapy | |
| CN105616402A (zh) | 治疗癌症的基于噻吨酮的自噬抑制剂疗法 | |
| JP2024056845A (ja) | 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子 | |
| Cutsem et al. | The role of chemotherapy in the current treatment of gastric cancer | |
| US20050282893A1 (en) | Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors | |
| JPWO2019140271A5 (enExample) | ||
| CN110573166A (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| US20220288404A1 (en) | Methods for applying tumor treating fields in combination with cancer treating therapeutics | |
| Twelves et al. | Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme | |
| US12233087B2 (en) | Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions | |
| CN112601527B (zh) | 用于有效预防和治疗的选择性抗癌剂 | |
| EP4568663A1 (en) | Compositions for and methods of precision cancer treatment | |
| CN116672345A (zh) | Parp抑制剂和细胞毒性剂的联合产品及其用途 | |
| EP4489752A1 (en) | Treatment of clear cell renal cell carcinoma | |
| Uher et al. | Neoadjuvant intratumoral MBT (A) immunotherapy prevents distant metastases and recurrence in murine models | |
| Gheware et al. | From bench to bedside and beyond: Challenges in direct: KRAS: targeting | |
| CA2515000A1 (en) | Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors | |
| US20210355223A1 (en) | Combinations for Treating Cancer |